A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance
2012; Elsevier BV; Volume: 33; Issue: 27 Linguagem: Inglês
10.1016/j.biomaterials.2012.05.049
ISSN1878-5905
AutoresHaihua Xiao, Haiqin Song, Qiang Yang, Haidong Cai, Ruogu Qi, Lesan Yan, Shi Liu, Yonghui Zheng, Yubin Huang, Tongjun Liu, Xiabin Jing,
Tópico(s)Nanoplatforms for cancer theranostics
ResumoA strategy of preparing composite micelles containing both cisplatin(IV) prodrug and paclitaxel was developed, i.e., synthesizing a cisplatin(IV) conjugate and a paclitaxel conjugate starting with the same biodegradable and amphiphilic block copolymer, and co-assembling the two conjugates. The composite micelles could release effective anticancer drug cisplatin(II) upon cellular reduction and PTX via acid hydrolysis once they came into the cancerous cells. Moreover, the composite micelles displayed synergistic effect in vitro and the combination therapy in micellar dosage-form led to reduced systematic toxicity and enhanced antitumor efficacy in vivo.
Referência(s)